For monocytes, differential expression of the surface markers CD14 and CD16 is correlated with the expression of other surface markers that can functionally categorize these cells (Savinetti et al., 2021); different categories are more prominent in the blood of patients with PD (Grozdanov et al., 2014), MS (Chuluundorj et al., 2014), and AD (Saresella et al., 2014), with the findings in AD also indicating a reduced amyloid uptake from these cells (Chen et al., 2020) which was not the case for PD patient derived cells in the same study. This evidence concerns the gene CD14 and Alzheimer disease.